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ABSTRACT  
Background: Predniso(lo)ne, alone or in combination with azathioprine, is the standard of care 
(SOC) therapy for autoimmune hepatitis (AIH). However, the SOC therapy is poorly tolerated or 
does not control disease activity in up to 20% of patients. We assessed the efficacy of 
mycophenolate mofetil (MMF) and tacrolimus as second-line therapy for patients with AIH. 
Patients and methods: We performed a retrospective study of data (from 19 centres in 
Europe, the United States, Canada, and China) from 201 patients with AIH who received 
second-line therapy (121 received MMF and 80 received tacrolimus), for a median of 62 
months (range, 6–190 months). Patients were categorized according to their response to SOC. 
Patients in group 1 (n=108) had a complete response to the SOC, but were switched to second 
line therapy due to side effects of predniso(lo)ne or azathioprine, whereas patients in group 2 
(n=93) had not responded to SOC. 
Results: There was no significant difference in the proportion of patients with a complete 
response to MMF (69.4%) vs tacrolimus (72.5%) (P=.639). In group 1, MMF and tacrolimus 
maintained a biochemical remission in 91.9% and 94.1% of patients, respectively (P=.682). 
Significantly more group 2 patients given tacrolimus compared to MMF had a complete 
response (56.5 % vs. 34%, P=.029) There were similar proportions of liver-related deaths or 
liver transplantation among patients given MMF (13.2%) vs tacrolimus (10.3%) (log-rank, 
P=.472). Ten patients receiving MMF (8.3%) and 10 patients receiving tacrolimus (12.5%) 
developed side effects that required therapy withdrawal. 
Conclusions: Long-term therapy with MMF or tacrolimus was generally well tolerated by 
patients with AIH. The agents were equally effective in previous complete responders who 
did not tolerate SOC therapy. Tacrolimus led to a complete response in a greater proportion of 
previous non-responder patients compared to MMF. 
 
Key words: autoimmune liver disease, simplified criteria, liver failure, liver transplantation. 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 4
INTRODUCTION  
Autoimmune hepatitis (AIH) is an immune-mediated liver disorder characterized by the 
presence of circulating autoantibodies and hypergammaglobulinemia with liver histology 
showing interface hepatitis [1]. AIH can progress to cirrhosis, liver failure and death if 
untreated [2].  
Corticosteroids, alone or in combination with azathioprine (AZA), remain the standard initial 
treatment of AIH. This therapy is effective in controlling inflammatory activity, reversing or 
preventing fibrosis progression and prolonging survival in the majority of patients [1-2]. 
However, up to 20% of patients do not respond, or are intolerant to standard treatment. There 
are reports of alternative immunosuppressive drug therapies including cyclosporine, 
methotrexate, 6-mercaptopurine, rituximab, everolimus, mycophenolate mofetil (MMF), 
tacrolimus, and infliximab, but there is no established rescue therapy in AIH [3-5].  
Different studies using MMF and tacrolimus as initial or rescue therapy have reported 
variable success rates. While some studies report that MMF is effective in non-responders and 
in patients that are intolerant to standard therapy, other studies suggest that MMF is an 
alternative only for AZA-intolerant patients [6-12]. Tacrolimus has also been successfully 
used in AIH patients who failed to respond to standard treatment [13-16].  The evidence 
regarding the efficacy and safety of these agents however is based on case series of limited 
size with short durations of follow up. No study has compared the efficacy of MMF to that of 
tacrolimus. These limitations preclude formally recommending MMF and/or tacrolimus for 
patients failing standard therapy. 
AIH is a rare disease and few patients are considered for second line therapy. To overcome 
these limitations and to add to our current knowledge, we conducted a large international 
multi-centre study to retrospectively evaluate the efficacy and safety of MMF and tacrolimus 
in AIH patients who were non-responsive or intolerant to standard immunosuppressive 
therapy.  
PATIENTS AND METHODS  
Study design  
We collected data from patients with an established AIH diagnosis from 19 centers across 
Europe, USA, Canada and China. AIH was diagnosed based on a combination of autoimmune 
serology, serum gamma globulin or immune globulin G (IgG) levels and compatible liver 
biopsy findings [17]. Overlaps of AIH with primary biliary cholangitis (PBC) and primary 
sclerosing cholangitis (PSC) were classified according to suggested international guidelines 
[18]. All patients who were treated with second line agents were identified. Patients with 
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insufficient information or non-compliance to therapy, those presenting with acute severe 
AIH as well as patients diagnosed with overlapping PBC or PSC were excluded. A flow chart 
for patient inclusion is presented in Figure 1.  
Baseline and follow-up data 
Collected patient data included sex, age and laboratory parameters according to Table 1. We 
recorded data on standard therapy (initial doses, therapy duration and response to treatment) 
and reasons for switching to second line therapy. Local pathologists in the participating 
centers evaluated liver biopsies; data from their reports were used in the study. Fibrosis was 
classified according to the METAVIR scoring system [19].  
Stratification based on reason for second line therapy 
Patients were divided into two groups depending on the reason for switching therapy to 
second line therapy. Group 1 patients had a complete response to standard therapy, but were 
switched to second line therapy due to steroid or AZA side effects. Group 2 patients had no 
response to standard therapy.  
In this study, a complete biochemical response was defined as normalization of serum 
aminotransferase and IgG levels at any time within six months after starting therapy. 
Anything less than a complete response was considered a non-response [1]. 
Statistical analysis  
Visual (histograms, probability plots) and analytical methods (Kolmogorov-Smirnov/Shapiro-
Wilk’s test) were used to determine the normality of continuous variables. Non-continuous 
variables were expressed as median (minimum-maximum). The χ 2 test, where appropriate, 
was used to compare the frequencies in different groups. The Wilcoxon signed-rank test was 
used for comparison of initial and final doses of MMF, tacrolimus and corticosteroid therapy. 
The Kaplan–Meier method was used to calculate mortality, from the time of second-line 
therapy to liver-related death and/or need for liver transplantation, using the log-rank test. 
SPSS software version 22 (SPSS, Chicago,IL,USA) and MedCalc version 14 (MedCalc, 
Ghent, Belgium) were used to perform statistical analysis and p<0.05 was considered 
statistically significant. 
RESULTS 
Characteristics of the patient population  
The medical records of 2260 patients with AIH were evaluated. Among 302 identified AIH 
patients treated with second line agents, 171 received MMF, 114 tacrolimus, 12 cyclosporine, 
2 everolimus and one patient each received cyclophosphamide, rituximab or methotrexate. 
The final study group included 201 AIH patients, 121 received MMF and 80 tacrolimus 
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(figure 1). The number of cases from each participating center is presented in supplementary 
table S1. 
All patients initially received standard of care (SOC) therapy (predniso(lo)ne 20–60, mg/day 
alone or in combination with AZA, 50–150 mg/day), except for eight patients who received 
budesonide in combination with AZA as initial therapy. AZA was stopped in all but two 
patients when MMF or tacrolimus was initiated. Patients received MMF and tacrolimus at 
doses of 0.5-2.0 g/day and 1-8 mg/day, respectively. The initial and final doses of MMF and 
tacrolimus were decided by the treating physician according to biochemical and clinical 
response. A combination of MMF and tacrolimus or a switch between these agents was 
considered for patients with a suboptimal response or drug side effects. 
The reasons for switching from SOC therapy to second line therapy are presented in Table 2. 
In the stratification based on response to SOC therapy, 108 (53.7%) were stratified to Group 1 
(intolerant to SOC), and 93 (46.3%) to Group 2 (non-responders to SOC). Among patients 
treated with MMF, 74 (61.2%) were in group 1 and 47 (38.8 %) in group 2.  In patients 
treated with tacrolimus, 34 (42.5 %) were in group 1 and 46 (57.5 %) in group 2 (Table 3). 
Response to second-line therapy  
The efficacy of MMF and tacrolimus in patients with AIH is presented in Table 3. Overall, 
the complete response rates were similar between MMF and tacrolimus treated patients 
(69.4% vs 72.5%, p=0.639). MMF and tacrolimus maintained biochemical response in 91.9% 
and 94.1% of patients in Group 1 (p=0.682). Significantly more group 2 patients given 
tacrolimus compared to MMF had a complete response (56.5% vs. 34%, p=0.029). The rates 
of complete response were significantly lower in group 2 than in group 1, both for patients 
treated with MMF and for patients treated with tacrolimus, p<0.001 (figure 2). 
In responders to second line therapy, the median initial and follow up doses for MMF were 
1500 (500-2000) and 1000 (0-2000) mg/day, and for tacrolimus 4 (1-8) and 3 (0-6) mg/day 
(p<0.001 for both). After initiation of MMF, the median steroid dose was decreased from 10 
(2.5-22.5) to 5 (0-10) mg/day, and after initiation of tacrolimus from 10 (5-50) to 5 (0-10) 
mg/day (p<0.001 for both). During maintenance therapy, the steroid therapy was completely 
withdrawn in 26 patients treated with MMF and in 20 patients treated with tacrolimus. 
Management of suboptimal response 
Seven non-responders to MMF showed a complete response after switching to tacrolimus. A 
combination of MMF and tacrolimus was used in eight suboptimal responders to either agent. 
This resulted in a complete response in six patients. 
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 Second line withdrawal and side effects 
Withdrawal of second line therapy was attempted in 14 of patients after long-term remission. 
Six patients (4 MMF, 2 tacrolimus) maintained biochemical remission during follow up but 
eight relapsed and were successfully re-treated with the previous regime.  
Side effects that required drug discontinuation were seen in 8.3 % (10/121) of MMF treated 
patients and in 12.5 % (10/80) of tacrolimus treated patients (p=0.326). MMF was stopped 
due to leukopenia (n=6), gastrointestinal side effects (n=3) and headache (n=1). MMF was 
switched to standard therapy (n=4) or to tacrolimus (n=5) and one patient declined further 
therapy. Moreover, MMF had to be discontinued due to pregnancy in two patients and due to 
lymphoproliferative disorder in one. Tacrolimus was stopped due to neurological side effects 
(n=4), hypertension and generalized edema (n=2), gastrointestinal side effects (n=2), hair loss 
(n=1) and renal failure (n=1). Tacrolimus was converted to standard therapy (n=5), to MMF 
(n=4) or to everolimus (n=1). 
Follow-up duration and outcome  
The median follow-up time of 62 (6-190) months was similar for patients treated with MMF 
and tacrolimus, 45 (6-169) vs. 73 (7–190) months, respectively (p=0.116). The 5 and 10 year 
follow up rates were 46.5% (53/114) and 22.8% (26/114) for MMF, 59.7% (52/87) and 16.1% 
(14/87) for tacrolimus. 
Liver biopsy was performed in 32 patients before second line therapy was initiated and in 24 
of these was repeated after a median 38 months (range 24–78) of biochemical remission. 
Fibrosis progression was observed in 20% (2/10) and 21.4% (3/14) of patients treated with 
MMF and tacrolimus, respectively (p=0.932). Eight of 32 patients had stage IV fibrosis before 
second-line therapy. In four of these eight patients, fibrosis remained stable or decreased 
while four progressed to liver failure. Five patients died from non-liver related causes, eight 
patients died from liver related causes and 16 patients underwent liver transplantation during 
follow up. At the time of writing this paper, 10 patients (8 MMF, 2 tacrolimus) were on a liver 
transplant waiting list. The rates of liver related death or transplantation were similar 
in the MMF (13.2%, n=15) and tacrolimus (10.3%, n=9) groups (log rank p=0.472, 
Figure 3).  
Discussion 
For the significant number of AIH patients that do not tolerate or have a suboptimal response 
to standard of care therapy, the future holds a risk for cirrhosis, liver failure, liver 
transplantation or death [20-22]. Additional treatment options beyond standard therapy with 
steroids and azathioprine are therefore needed. Over the years, several second line options 
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have been evaluated but reports have been limited to small case series. This study represents 
the largest cohort of patients exposed to alternative immunosuppression for the management 
of AIH. Derived from many treatment centers across Europe, China and North America, it 
represents a real-world experience of both MMF and tacrolimus in AIH.  
In earlier studies [6, 7, 23], MMF induced or maintained biochemical remission in 43-88% of 
AZA-intolerant patients. Unlike these studies, we did not consider progression to liver failure 
or stopping MMF due to side effects to be the definition of treatment failure, if the patient 
continued to be in biochemical remission. This difference in definition criteria may contribute 
to the higher success rate of MMF in our study group. 
Existing data regarding the efficacy of MMF in non-responders to SOC therapy are 
inconclusive. Some reports found MMF effective, whereas other studies reported complete 
response rates below 25% in non-responders to SOC therapy [6-10]. Our study results, with a 
34 % success rate of MMF in non-responders to SOC therapy, are consistent with the latter 
reports.  
Multiple small observational reports have evaluated tacrolimus as second line therapy in AIH. 
In three studies, tacrolimus promoted or maintained remission in 93% (31/33) of treated 
patients [13-15]. In another study, tacrolimus induced biochemical remission in 77% (7/9) of 
acute AIH [24]. More recently, Ni Than et al reported that 52% (9/17) of AIH patients 
responded to tacrolimus [25]. We found a 56.5% (26/46) complete response rate to tacrolimus 
in patients failing SOC therapy. Collectively, our and earlier results suggest that tacrolimus 
may be superior to MMF as an alternative therapy in patients with non-response to standard 
therapy. 
In our study, seven patients entered remission after switching from MMF to tacrolimus. A 
combination of MMF and tacrolimus induced a biochemical response in six patients, after an 
insufficient response to single therapy with either agent alone. Recently, Weiler et al. reported 
successful rescue treatment with infliximab in 11 AIH patients, of whom a majority failed to 
respond to MMF and/or tacrolimus [4]. These results suggest that a significant proportion of 
AIH patients still need alternative treatment strategies. Molecular interventions that block 
multiple and different pathways or that strengthen immune tolerance may provide paths 
forward in the treatment of AIH. There is a risk for an increased frequency of drug-induced 
complications with combination therapy. Balancing the potential treatment related side effects 
from over-immunosuppression may prove to be a challenge. 
We particularly focused on severe drug related side effects of MMF or tacrolimus that 
resulted in therapy withdrawal. Therefore, information about minor side effects that were 
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tolerated or resolved with dose adjustments were not collected and analyzed in detail. The 
participating centers reported no cases of skin malignancies and only one case with 
lymphoproliferative disorder during MMF therapy. However, the case data forms did not 
specifically ask for information on malignancies. In two patients MMF was discontinued 
during pregnancy. The teratogenic potential of MMF should be carefully explained to all 
patients of childbearing age. The retrospective nature of our study may overestimate the 
safety profile of MMF or tacrolimus. Considering the long follow-up and the available 
collected data, we can conclude that both agents appear to be safe alternatives for long-term 
use in AIH.  
A complete biochemical response, the prevention of fibrosis progression and the permanent 
withdrawal of immunosuppression are desirable objectives in AIH [2]. Of note, 21% of 
patients who were treated with MMF/tacrolimus had fibrosis progression in follow-up 
biopsies despite maintaining long-term complete biochemical response. This finding is in line 
with a recent large study on AIH [21]. Successful long-term withdrawal of MMF or 
tacrolimus was achieved in six of our patients. Since few alternative therapies are available if 
MMF and/or tacrolimus fail to control disease activity, we cannot recommend routinely 
attempting discontinuation of second line agents.  
Overall, the frequency of liver-related death/transplantation was not different, despite a higher 
biochemical response rate in the tacrolimus groups. This may be due to some of the MMF 
non-responders progressing to liver failure with the complication successfully being managed 
by switching to or combining therapy with tacrolimus. 
Second line agents are more expensive than standard immunosuppression and cost-
effectiveness may be an important issue in patients treated with MMF or tacrolimus [22]. 
Predniso(lo)ne, at daily doses exceeding 10 mg for more than two years is associated with 
several side effects including osteoporosis, bone fractures, diabetes, hypertension, obesity and 
psychiatric suffering [1]. Suboptimal AIH therapy is also expensive. Progression to liver 
failure resulting in experimental medication, morbidity, liver transplantation and other health 
care efforts comes at a price. In our study, MMF and tacrolimus were tapered to minimal 
effective doses per biochemical response. Steroid therapy was also possible to reduce to low 
doses and that undoubtedly minimized its side effects. AIH is a lifelong condition for most 
patients. Beyond the market price of drugs, all these factors have to be balanced into the 
equation when cost-effectiveness is discussed.  
Our study has all the limitations of a retrospective study. Potentially relevant baseline genetic, 
serologic and histological features that might affect the therapeutic response were not fully 
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available for all patents. This limitation precludes identifying independent predictors of the 
response to therapy with MMF and tacrolimus. Indications, drug doses and types of second 
line therapy were decided on in a non-standardized way. The initial doses of standard therapy 
and steroid tapering protocols were not identical among physicians. Also, some patients were 
initially treated by the referring center. All these factors may lead to a bias in our results. 
However, only expert centers participated in the study and we are confident that the 
management of these patients was of high standard according to international guidelines. Our 
study reflects “real life” experiences and we hope that it will be helpful to clinicians in the 
selection of an appropriate second line therapy.  
In conclusion, the results of this retrospective and non-comparative study suggest that MMF 
and tacrolimus are safe alternative agents with durable immunosuppressive effects in the 
treatment of AIH in a significant proportion of patients. MMF and tacrolimus are equally 
capable of inducing or maintaining remission in responders to standard of care medication, 
but tacrolimus performed better than MMF for patients previously failing to standard therapy. 
However, approximately one third of our patients showed a suboptimal response to second 
line therapy and some progressed into liver failure. This emphasizes the need for additional 
novel alternative therapies. 
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Table 1. General features of patients at time of diagnosis and before second line therapy 
Characteristics of the study population at the time of AIH diagnosis 
 Overall 
n=201 
MMF 
n=121 
Tacrolimus 
n=80 
Gender (Female), n (%) 156(77.4) 96 (79.3) 60 (75) 
Age (years) 35 (7-76) 41 (7-76) 31 (10-67) 
ALT x UNL  15 (1.8-87.0) 15.5 (1.8-87.0) 12.3 (1.8-49.0) 
AST x UNL  13.3 (1.8-92.3) 13.8 (1.8-92.3) 12.0 (2.1-43.9) 
ALP x UNL  1.1 (0.2-6.5) 1.3 (0.3-6.5) 0.8 (0.2-3.5) 
Bilirubin (x UNL) 2.3 (0.3-15.5) 2.8 (0.3-13.5) 1.9 (0.3-15.5) 
IgG x UNL  1.6 (0.5-4.1) 1.4 (0.6-3.8) 1.7 (0.5-4.1) 
ANA, n (%)* 127 (68.6) 80(70.8) 47 (65.3) 
SMA, n (%) ** 120 (65.6) 70 (61.4) 50 (72.5) 
LKM, n (%) *** 4(2.3) 3(3.0) 1(1.4) 
Fibrosis scores (III-IV), n (%) ****  95 (54.3) 57 (54.8) 38 (53.5) 
Initial steroid dose, mg/d 30 (20-60) 30 (20-60) 30 (20-60) 
  Group 1 30 (20-60) 30 (20-60) 30 (20-60) 
  Group 2 30 (25-60) 30 (25-60) 30 (30-60) 
Characteristics of the study population before second-line therapy  
 Overall 
 
MMF 
 
Tacrolimus 
 
Time to second line (months) 12 (2-256) 12(2-256) 10 (3-182) 
ALT x UNL  0.9 (0.3-39.2) 0.9(0.3-39.2) 2.1 (0.4-29.6) 
AST x UNL  1.0 (0.4-31.5) 1.0(0.4-31.5) 2.0 (0.5-25.5) 
ALP x UNL  0.9 (0.3-5.2) 0.9(0.3-5.2) 0.8 (0.4-2.7) 
Bilirubin xUNL 0.9 (0.2-11.2) 0.9(0.3-9.9) 0.9 (0.2-11.2) 
IgG x UNL  1.0 (0.4-2.1) 0.9 (0.4-2.1) 1.1 (0.4-1.9) 
Fibrosis scores (III-IV), n (%) ***** 22 (68.8) 12 (75.0) 10 (62.5) 
*ANA, was available in 185; **SMA, in 183; ***LKM, in 170; ****liver biopsy, in 175; 
***** Biopsy before second line, in 32.  Group 1, patients with complete response to standard 
therapy; Group 2, patients with no response to standard therapy. 
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Table 2. Reasons for switching therapy to MMF or tacrolimus 
 Overall  
n=201 
MMF 
n=121 
Tacrolimus  
n=80 
AZA intolerance, n (%) 78 (38.8) 56 (46.3) 22 (27.5) 
Steroid side effects n (%)  30 (14.9) 18 (14.9) 12 (15.0) 
Non response to standard therapy, n (%) 93(46.3) 47(38.8) 46 (57.5) 
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Table 3. Efficacy of MMF and tacrolimus in patients with autoimmune hepatitis 
        
 
      MMF  
     (n=121)  
   Tacrolimus  
    (n=80) 
P value  
Response Complete (all)  84 (69.4%)  58 (72.5%)  0.639 
 
Group I (n=108) n=74 n=34  
Complete  Response 
         
68 (91.9%) 
 
32 (94.1%) 
 
0.682 
Group II (n=93) n=47 n=46  
Complete  Response 
         
16 (34.0%) 
 
26 (56.5%) 
 
0.029 
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Supplementary table S1 
The participating centers in alphabetical order and the number of contributed patients 
Participating centre Number of cases 
Brighton and Sussex University, UK 6 
CHU Reims, France 9 
Ege University, Turkey 5 
Hacettepe University, Turkey 7 
Karolinska Institutet, Sweden 45 
Kings College Hospital, UK 28 
Leipzig University, Germany 32 
Mount Sinai Medical Center, USA 8 
Numune Education Hospital, Turkey 8 
Shanghai Jiao Tong University, China 11 
Skane University Hospital, Sweden 8 
Umeå University, Sweden 7 
University of Alberta, Canada 28 
University of Barcelona, Spain 2 
University of Bologna, Italy 10 
University of British Columbia, Canada 23 
University of California San Francisco, USA 4 
University of Copenhagen, Denmark 57 
University of Gothenburg, Sweden 4 
In total 19 centers   In total 302 patients 
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Figure legends: 
 
Figure 1: Study flow chart for patient inclusion.  
 
Figure 2: Therapy response rates for patients treated with MMF and tacrolimus. Complete 
response rates were significantly decreased through group1 to group 2. (p<0.001 for both). 
 
Figure 3: Cumulative survival from liver-related death and transplantation in patients treated 
with MMF and tacrolimus (log-rank, p=0.472). 
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